FDA Expands Marstacimab Indication in Hemophilia A and B - Poll - MDSpire

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor populations.

  • By

  • Kathryn Wighton

  • June 8, 2026

  • 3 min

Share

Original Source(s)

FDA Expands Marstacimab Indication in Hemophilia A and B

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Correction: Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

How Many US Clinicians Come From Banned Countries?

Counties with at least one clinician from a banned country were more likely to be designated primary care shortage areas.

Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome